Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

<p class="first" id="d2311071e312">In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) on the clinical benefit of sodium-glucose cotransporter 2 inhibition is unknown. </p>

Related collections

Author and article information

Journal

Title: Circulation

Abbreviated Title: Circulation

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Print): 0009-7322

ISSN (Electronic): 1524-4539

Publication date Created: March 18 2019

Publication date (Electronic): March 18 2019

Affiliations

[1 ]Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Japan

[2 ]Medicine, Cardiology Division, Massachusetts General Hospital, Boston, MA

[3 ]Diabetes Unit Devision of Internal Medicine, Hadassah Hebrew University Hospital, Israel

[4 ]TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

[5 ]Internal Medicine, Hadassah Hebrew University Hospital, Israel

[6 ]TIMI Study Group, Brigham and Women's Hospital, Boston, MA

[7 ]Statistics, TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, MA

[8 ]TIMI Study Group, Brigham and Women's Hospital Heart & Vascular Center, Boston, MA

[9 ]Harvard Medical School, Brigham and Women's Hospital Heart and Vascular Center, Boston, MA

[10 ]Medicine, Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Canada

[11 ]Internal Medicine-Cardiology, University of Texas-Southwestern Med Ctr, Dallas, TX

[12 ]Institute of Ageing and Chronic Disease, University of Liverpool, United Kingdom

[13 ]Colorado Prevention Center, CO

[14 ]Medicine, Brigham and Women's Hospital, Boston, MA

[15 ]Cardiolovascular Medicine, Brigham and Women's Hospital, Boston, MA

[16 ]Department of Medicine, Cardiology, Tokai University School of Medicine, Japan

[17 ]Biometrics, AstraZeneca, Sweden

[18 ]GMD, AstraZeneca Gothenburg, Sweden

[19 ]AstraZeneca R&D, CVRM, Sweden

[20 ]Biopharmaceuticals, AstraZeneca Gothenburg, Sweden

[21 ]Medicine, BWH/TIMI Study Group, Boston, MA

Article

DOI: 10.1161/CIRCULATIONAHA.119.040130

PubMed ID: 30882238

SO-VID: d5ff2581-bb63-4db8-a745-61046bea7850

History

Data availability:

Comments

Comment on this article

scite_

Cited by 218

See all cited by